相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus
Alberto Martini et al.
JOURNAL OF RHEUMATOLOGY (2019)
Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis
Kiem Oen et al.
ARTHRITIS CARE & RESEARCH (2018)
Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial
Kamal N. Bharucha et al.
JOURNAL OF RHEUMATOLOGY (2018)
Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology
Hermine I. Brunner et al.
PEDIATRIC RHEUMATOLOGY (2018)
Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis
Xiaoping Zhang et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
Alan Kivitz et al.
RHEUMATOLOGY AND THERAPY (2016)
Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis Results From a Phase III Trial
Fabrizio De Benedetti et al.
ARTHRITIS & RHEUMATOLOGY (2015)
The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort
Jaime Guzman et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
Hermine I. Brunner et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score
Alessandro Consolaro et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
Emilio Besada
PATIENT PREFERENCE AND ADHERENCE (2014)
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score
Alessandro Consolaro et al.
ARTHRITIS AND RHEUMATISM (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Clarification on Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetic Studies
Yaning Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)
Nicolino Ruperto et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2011)
Juvenile idiopathic arthritis
Berent Prakken et al.
LANCET (2011)
American College of Rheumatology Provisional Criteria for Defining Clinical Inactive Disease in Select Categories of Juvenile Idiopathic Arthritis
Carol A. Wallace et al.
ARTHRITIS CARE & RESEARCH (2011)
Subset Analysis of Patients Experiencing Clinical Events of a Potentially Immunogenic Nature in the Pivotal Clinical Trials of Tocilizumab for Rheumatoid Arthritis: Evaluation of an Antidrug Antibody ELISA Using Clinical Adverse Event-Driven Immunogenicity Testing
Kay Stubenrauch et al.
CLINICAL THERAPEUTICS (2010)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Development and Validation of a Composite Disease Activity Score for Juvenile Idiopathic Arthritis
Alessandro Consolaro et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Treatment choices, preferences and decision-making by patients with rheumatoid arthritis
Frances Chilton et al.
MUSCULOSKELETAL CARE (2008)
Juvenile idiopathic arthritis
Angelo Ravelli et al.
LANCET (2007)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
M Mihara et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
分享论文
